Spiegl-Kreinecker Sabine, Buchroithner Johanna, Elbling Leonilla, Steiner Elisabeth, Wurm Gabriele, Bodenteich Angelika, Fischer Johannes, Micksche Michael, Berger Walter
Department of Neurosurgery, Landesnervenklinik Wagner-Jauregg Hospital, Linz, Austria.
J Neurooncol. 2002 Mar;57(1):27-36. doi: 10.1023/a:1015735815111.
The poor prognosis of glioma patients is partly based on the minor success obtained from chemotherapeutic treatments. Resistance mechanisms at the tumor cell level may be, in addition to the blood-brain barrier, involved in the intrinsic chemo-insensitivity of brain tumors. We investigated the expression of the drug-transporter proteins P-glycoprotein (P-gp) and multidrug-resistance protein 1 (MRP1) in cell lines (N = 24) and primary cell cultures (N = 36) from neuroectodermal tumors, as well as in brain tumor extracts (N = 18) and normal human astrocytes (N = 1). We found that a considerable expression of P-gp was relatively rare in glioma cells, in contrast to MRP1, which was constitutively overexpressed in cells derived from astrocytomas as well as glioblastomas. Also, normal astrocytes cultured in vitro expressed high amounts of MRPI but no detectable P-gp. Meningioma cells frequently co-expressed P-gp and MRP1, while, most of the neuroblastoma cell lines express higher P-gp but lower MRP1 levels as compared to the other tumor types. Both, a drug-exporting and a chemoprotective function of P-gp as well as MRP1 could be demonstrated in selected tumor cells by a significant upregulation of cellular 3H-daunomycin accumulation and daunomycin cytotoxicity via administration of transporter antagonists. Summing up, our data suggest that P-gp contributes to cellular resistance merely in a small subgroup of gliomas, but frequently in neuroblastomas and meningiomas. In contrast, MRP1 is demonstrated to play a constitutive role in the intrinsic chemoresistance of gliomas and their normal cell counterpart.
胶质瘤患者预后较差,部分原因在于化疗取得的成效有限。除血脑屏障外,肿瘤细胞水平的耐药机制也可能与脑肿瘤固有的化疗不敏感性有关。我们研究了药物转运蛋白P-糖蛋白(P-gp)和多药耐药蛋白1(MRP1)在神经外胚层肿瘤细胞系(N = 24)、原代细胞培养物(N = 36)、脑肿瘤提取物(N = 18)以及正常人星形胶质细胞(N = 1)中的表达情况。我们发现,与MRP1相比,P-gp在胶质瘤细胞中的大量表达相对少见,MRP1在源自星形细胞瘤和胶质母细胞瘤的细胞中组成性过表达。此外,体外培养的正常星形胶质细胞表达大量MRP1,但未检测到P-gp。脑膜瘤细胞经常共表达P-gp和MRP1,而与其他肿瘤类型相比,大多数神经母细胞瘤细胞系表达较高水平的P-gp但较低水平的MRP1。通过给予转运体拮抗剂显著上调细胞3H-柔红霉素蓄积和柔红霉素细胞毒性,在选定的肿瘤细胞中证实了P-gp以及MRP1的药物外排和化学保护功能。总之,我们的数据表明,P-gp仅在一小部分胶质瘤中导致细胞耐药,但在神经母细胞瘤和脑膜瘤中较为常见。相比之下,MRP1在胶质瘤及其正常细胞对应物的固有化疗耐药中起组成性作用。